Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

• Results Overview

  Crisaborole ointment 2% was found to be safe and effective when used twice daily in infants with mild-to-moderate eczema, with most side effects being mild and occurring at the application site.

• Study Summary

  Num Participants:

  137

  Study Type:

  Observational

  Control Group:

  None

  Efficacy End Points Treatment:

  {'ISGA clear/almost clear': 30.2, 'EASI score': -57.5, 'POEM score': -8.5}

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Application Site Pain	Low	3.6
  Application Site Discomfort	Low	2.9
  Erythema	Low	2.9

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected